Tradercommunity Clickoptions Forum

[Newsagent]

PR inside: Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome ...

(PR-inside.com) Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027

SAN FRANCISCO, CA / ACCESS Newswire / September 29, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of an abstract on preliminary results of an ongoing open-label study of the company's crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG ..

https://reports.pr-inside.com/prelimina ... 228435.htm
Copyright PR-Inside.com 2026